Rachel Lutz

Articles

Researchers Explore Benefits of Using Composite End Points in COPD Trials

July 17, 2020

Using composite endpoints to predict clinically important deterioration in chronic obstructive pulmonary disease (COPD) could help investigators assess disease activity in clinical trials and better manage individual patients, according to a recent study.

Disability Accumulation in Multiple Sclerosis Is Independent of Relapses

June 22, 2020

The study authors tested the risk-reducing effects of ocrelizumab compared with interferon β-1a for treatment of multiple sclerosis disability accumulation, with ocrelizumab showing better results in lowering disability accumulation scores.